Armen Shanafelt has bought stock on 2 days since Jul 2017

Armen B. Shanafelt, PhD is a biotechnology executive, investor, and board director who has served as a Director and 10% owner of Surface Oncology, Inc. (SURF), where he has held significant equity and has been an active corporate insider in the company’s stock.( He joined the Surface Oncology board at the time of its early financing and helped guide the Cambridge, Massachusetts–based cancer immunotherapy company through IPO-stage growth and portfolio development, drawing on his background in pharmaceutical R&D and venture investing.(

Shanafelt is President of ABShanafelt Advisory, LLC, a life sciences advisory firm, and has previously been a general partner at Lilly Ventures and a senior R&D leader at Eli Lilly and Company, where he served as one of several Chief Scientific Officers responsible for generating and advancing new therapeutic programs.( He also serves as a director at Aeglea BioTherapeutics and has been involved in multiple successful biotech IPOs, including AGLE, ALRN, PTGX, STRO, and SURF.( Shanafelt holds a PhD in Chemistry from the University of California, Berkeley and a BS in Chemistry and Physics from Pacific Lutheran University, providing a strong scientific foundation for his work in drug discovery, early development strategy, and board-level governance in the biopharmaceutical sector.(

Written by Perplexity from public sources.